
HPLC METHOD DEVELOPMENT FOR PHARMACEUTICALS

Edited by Satinder Ahuja Henrik Rasmussen



VOLUME 8 Series Editor Satinder Ahuja
SEPARATION SCIENCE AND TECHNOLOGY



HPLC METHOD DEVELOPMENT FOR PHARMACEUTICALS

This is Volume 8 of

SEPARATION SCIENCE AND TECHNOLOGY

A reference series edited by Satinder Ahuja and Henrik Rasmussen

HPLC METHOD DEVELOPMENT FOR PHARMACEUTICALS

Edited by

Satinder Ahuja

Ahuja Consulting, Inc., Calabash, North Carolina

Henrik Rasmussen

Johnson & Johnson Pharmaceutical Research and Development, LLC Raritan, New Jersey



Amsterdam – Boston – Heidelberg – London – New York – Oxford – Paris – San Diego – San Francisco – Singapore – Sydney – Tokyo Academic Press is an imprint of Elsevier 84 Theobald's Road, London WC1X 8RR, UK Radarweg 29, PO Box 211, 1000 AE Amsterdam, The Netherlands Linacre House, Jordan Hill, Oxford OX2 8DP, UK 30 Corporate Drive, Suite 400, Burlington, MA 01803, USA 525 B Street, Suite 1900, San Diego, CA 92101-4495, USA

First edition 2007

Copyright © 2007 Elsevier Inc. All rights reserved

No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means electronic, mechanical, photocopying, recording or otherwise without the prior written permission of the publisher.

Permissions may be sought directly from Elsevier's Science & Technology Rights Department in Oxford, UK: phone (+44) (0) 1865 843830; fax (+44) (0) 1865 853333; e-mail: permissions@elsevier.com. Alternatively you can submit your request online by visiting the Elsevier web site at http://elsevier.com/locate/permissions, and selecting Obtaining permission to use Elsevier material

Notice

No responsibility is assumed by the publisher for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products, instructions or ideas contained in the material herein. Because of rapid advances in the medical sciences, in particular, independent verification of diagnoses and drug dosages should be made

ISBN: 978-0-12-370540-2

For information on all Academic Press publications Visit our website at books elsevier.com

Printed and bound in Italy

07 08 09 10 11 10 9 8 7 6 5 4 3 2 1

Working together to grow libraries in developing countries www.elsevier.com | www.bookaid.org | www.sabre.org

PREFACE xiii CONTRIBUTORS xv

I. Overview of HPLC Method Development for Pharmaceuticals

SATINDER AHUJA

I.	Introduction 1
II.	Theoretical Considerations 2
III.	HPLC Columns and Column Packings 2
IV.	Column Selection 3
V.	Chiral Separations 3
VI.	Contemporary HPLC 4
VII.	Hyphenated Methods 5
VIII.	Sample Preparation 5
IX.	Instrument Qualification and Software Validation 6
X.	Pharmaceutical Development 6
XI.	Drug Discovery 7
XII.	Early Phase Method Development 8
XIII.	Late Phase Development 8
XIV.	In-Process Testing 9
XV.	Method Development for Biomolecules 9
XVI.	Method Validation 10
VII.	Troubleshooting 10
VIII.	Molecularly Imprinted Polymers 10
	References 11

Vİ CONTENTS

2. HPLC Theory

Y.V. KAZAKEVICH

A I		12
Δ	bstract	-13

- I. Introduction 13
- II. Basic Chromatographic Descriptors 14
- III. Efficiency 15
- IV. Resolution 20
- V. Main Components of the Retention Mechanism 22
- VI. General Column Mass Balance 24
- VII. Partitioning Model 27
- VIII. Adsorption Model 28
- IX. Void Volume Considerations 29
- X. Thermodynamic Relationships 31
- XI. Secondary Equilibria 35
- XII. Salt Effect 37
- XIII. Effect of Different Counteranions 38
- XIV. Inclusion of Secondary Equilibria in the Mass Balance 40
- XV. Conclusions 43 References 43

3. HPLC Columns and Packings

UWE D. NEUE, BONNIE A. ALDEN, EDWARD R. GROVER, ERIC S. GRUMBACH, PAMELA C. IRANETA, AND ALBERTO MÉNDEZ

Abstract 45

- I. Introduction 46
- II. Column Chemistry 47
- III. Speed and Resolution 68
- IV. Specialty Columns from Nanobore to Preparative Chromatography 77
- V. Summary 80 References 80

4. Column Characterization and Selection

DÓRA VISKY

- I. Introduction 86
- II. Characteristics of RP-HPLC Columns and Chromatographic Tests 90
- III. Column Classification and Selection 101
- IV. Conclusions 104
 Acknowledgment 105
 References 105

5. Chiral Separations

XIANDE WANG, WEIYONG LI, AND HENRIK RASMUSSEN

Abstract 111

- I. Introduction 112
- II. Separation of Enantiomers on HPLC Chiral Stationary Phases 115
- III. Practical Guidelines to Chiral HPLC of Pharmaceuticals 135
- IV. Conclusions 137 References 138

6. Contemporary Liquid Chromatographic Systems for Method Development

MICHAEL E. SWARTZ

Abstract 145

- I. Introduction 146
- II. Traditional Instrumentation for HPLC Method Development 147
- III. Contemporary Method Development Systems 153
- IV. Migrating Methods from HPLC to UPLC 169
- V. UPLC Applications in Pharmaceutical Analysis 174
- VI. Summary and Conclusions 183 Acknowledgments 184

References 185 Further Reading 186

7. Hyphenated Techniques

DANIEL L. NORWOOD, JAMES O. MULLIS, AND THOMAS N. FEINBERG

Abstract 189

- I. Introduction and Background 190
- II. Combined Liquid Chromatography/Mass Spectrometry 191
- III. Combined Liquid Chromatography/Nuclear Magnetic Resonance Spectroscopy 218
- IV. Conclusions 231
 Acknowledgments 231
 References 232

8. HPLC Sample Preparation

GREGORY C. SLACK AND NICHOLAS H. SNOW

- I. Introduction 238
- II. Fundamentals of Extraction and Chemical Equilibrium 239
- III. Choice of Samples Preparation 245

VIII CONTENTS

- IV. Direct Injection 246
- V. Liquid-Liquid Extraction 247
- VI. Solid-Phase Extraction 248
- VII. Solid Samples 254
- VIII. Additional Sample Preparation Methods 256
 - IX. Conclusions 263 References 263

9. Instrument Qualification and Software Validation

DAVE VAN GFFL

Abstract 270

- I. Introduction 270
- II. Definitions 271
- III. Qualification Model 278
- IV. Discussion: Case Study HPLC 291
- V. Summary and Conclusions 294 Acknowledgments 295

References 295

10. Pharmaceutical Development: From Pre-Clinical to Post Approval

KEVIN C. BYNUM

Abstract 297

- I. Introduction 298
- II. The Role of HPLC in Drug Discovery 300
- III. The Role of HPLC in Pre-clinical Development 303
- IV. The Role of HPLC in Clinical Development 307
- V. Post Approval 312
- VI. Conclusions 315

References 315

II. HPLC Method Development for Drug Discovery LC-MS Assays in Rapid PK Applications

XIAOYING XU

- I. Introduction 318
- II. Tandem MS Selected Reaction Monitoring (SRM)Development 319
- III. HPLC Method Development 322
- IV. Sample Preparation 324

- V. Matrix Effects 329
- VI. Background Interference: Enhanced Mass Resolution Strategy 334
- VII. Limit of Quantitation, Dynamic Range and Linearity 340
- VIII. Assay Samples and Generate Pharmacokinetic Reports 344
- IX. Conclusions 345
 Acknowledgment 345
 References 345

12. HPLC Method Development in Early Phase Pharmaceutical Development

HENRIK T. RASMUSSEN, KELLY A. SWINNEY, AND SHEETAL GAIKI

- Abstract 353
- I. Introduction 354
- II. Forced Decomposition and Impurity Profiling 355
- III. Orthogonal Screening 357
- IV. Method Selection and Optimization 362
- V. Additional Methods 366
- VI. Setting the Stage for Late Phase HPLC Method Developments 367
- VII. Conclusions 369
 Acknowledgments 369
 References 369

13. HPLC Method Development in Late Phase Pharmaceutical Development

M. ILIAS JIMIDAR AND MAURITS DE SMET

- Abstract 373
- I. Introduction 374
- II. Goals of Development 375
- III. Planning Phase 377
- IV. Method Development Phase 382
- V. Method Evaluation Phase 394
- VI. Method Transfer Phase 398
- VII. Method Performance Monitoring and Feedback 400
- VIII. Method Development Cycle Times and Documentation 403
- IX. Conclusions 403 References 404

14. Use of HPLC for In-process Testing

CHRISTINE F. RICHARDSON

Abstract 407

I. Introduction 407

X CONTENTS

- II. Various Examples of In-Process Testing in Drug Substance Development 409
- III. Fast HPLC 419
- IV. In-Process Testing in Chemical Production 420
- V. In-Process Testing in Pharmaceutical Production 422
- VI. Conclusions and Future Directions 423
 Acknowledgments 423
 References 423

15. Method Development for Biomolecules

JULEE L. DRIVER AND DOUGLAS E. RAYNIE

Abstract 425

- I. Introduction 426
- II. Protein and Peptide Separations by HPLC 430
- III. Case Studies 434
- IV. Summary and Conclusions 437 Abbreviations 438 References 438

16. Method Validation

M. ILIAS JIMIDAR, PATRICK HEYLEN, AND MAURITS DE SMET

Abstract 441

- I. Introduction 442
- II. Validation Process 444
- III. Validation Characteristics 444
- IV. Additional Validation Characteristics 450
- V. Robustness Testing 452
- VI. Conclusions 457 References 457

17. Troubleshooting in High Performance Liquid Chromatography

HAROLD MCNAIR AND LEE N. POLITE

- I. Introduction 460
- II. Problems Observed in Chromatograms 460
- III. Operating Parameters 468
- IV. Leaks 472
- V. Pressure Problems 474
- VI. Troubleshooting Action Plan 475
- VII. Conclusions 477 References 477
 - Internet Resources 477

18. Molecularly Imprinted Polymers as Sorbents for Separations and Extractions

MYRA T. KOESDJOJO, YOLANDA H. TENNICO, AND VINCENT T. REMCHO

- I. Introduction 479
- II. MIP Theory 481
- III. Synthesis 487
- IV. Use of Imprinted Polymers in Separation Science 491
- V. Pharmaceutical Application for MIPs 493
- VI. Pros and Cons of MIP Sorbents 495
- VII. Conclusions and Future Outlook 496 References 497

This Page Intentionally Left Blank

PREFACE

High pressure, or high performance, liquid chromatography (HPLC) is the method of choice for checking purity of new drug candidates, monitoring changes during scale up or revision of synthetic procedures, evaluating new formulations, and running control/assurance of the final drug product.

While numerous texts on HPLC are available, there are several unique concerns for pharmaceuticals that have not been discussed previously in one single book:

- Strategies have to be developed for instrument qualification and validation to meet various regulatory requirements.
- HPLC methods need to meet stringent validation requirements before they are utilized for any pharmaceutical evaluations.
- Impurities and degradation products to be separated are frequently not known and must be elucidated as part of the method development process.

The aim of this book is to provide an extensive overview of modern HPLC method development that addresses these unique concerns. For the purpose of providing a single source of information, an attempt has to been made to address all topics relevant to HPLC method development. The book is comprised of two major sections:

1. Review and update of the current state of the art and science of HPLC, including theory, modes of HPLC, column chemistry, retention mechanisms, chiral separations, modern instrumentation (including ultrahigh-pressure systems), and sample preparation.

XÍV PREFACE

Emphasis has been placed on implementation and on providing a practical perspective.

- 2. Focus on unique requirements for HPLC in a pharmaceutical setting. These include:
 - Strategies for software and hardware validation to allow for use in a regulated laboratory.
 - An overview of the pharmaceutical development process (clinical phases, chemical, and pharmaceutical development activities) to bring method development discussion into context.
 - A comprehensive discussion of how HPLC is used in each phase of pharmaceutical development and how methods are developed to support activities in each phase.
 - A discussion of method validation activities that provides an extension of ICH guidelines (i.e., provides an interpretation of ICH guidelines).
 - A comprehensive discussion of troubleshooting and prevention of problems.
 - A review of the emerging field of molecularly imprinted polymers and its potential applications in pharmaceutical analyses.

The book is intended to be particularly useful for both novice and experienced HPLC method development chemists in the pharmaceutical industry and for managers who are seeking to update their knowledge. We would like to thank the authors for their contributions that will make this book serve as a definitive reference source of HPLC method development for researchers, analysts, managers, and regulators of the pharmaceutical industry.

Satinder (Sut) Ahuja Henrik Rasmussen